Blood Biomarkers for Screening of Alzheimer's Disease

Peking University

Status: Enrolling

Conditions: Blood Biomarkers; Alzheimer's Disease

Treatments: Diagnostic Test: Blood biomarker

Study type: Observational

Funder types: Other

Identifiers

NCT06477484

2024SF35

Details and patient eligibility

About

The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:

• to identify core blood biomarker suitable for early screening of AD.
• to establish a comprehensive model for the early identification of AD.

Enrollment: 180 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age ≥ 50 years;
• AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
• Signed informed consent form.

Exclusion criteria

• The presence of other disorders that can cause cognitive impairment;
• Unable to cooperate with the completion of cognitive assessment;
• Refusal to draw blood.

Trial design

180 participants in 1 patient group

different stages of individuals with Alzheimer's disease

Treatment:

Diagnostic Test: Blood biomarker